MedTrace Logo

Hyperspectral Drusen Classification

NCT06860555 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2025-03-06

No results posted yet for this study

Summary

This observational, cross-sectional study is designed to explore the feasibility to extract spatial-spectral features from hyperspectral retinal images captured with Optina Diagnostics' MHRC that are characteristic to the different types of drusenoid deposits associated with dry age-related macular degeneration.

Conditions

  • Dry Age Related Macular Degeneration

Interventions

DEVICE

Mydriatic Hyperspectral retinal Camera, (MHRC) and Optical coherence tomography (OCT)

Imaging with the MHRC and optical coherence tomography (OCT).

Sponsors & Collaborators

  • Optina Diagnostics Inc.

    lead INDUSTRY

Principal Investigators

  • Dr. Jean Daniel Arbour, MD, FRCSC · Clinique Ophtalmologique 2121, 2121 rue Sherbrooke Ouest, Montréal, Québec, H3H 1G6

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-08
Primary Completion
2023-08-15
Completion
2023-08-15
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06860555 on ClinicalTrials.gov